X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (47) 47
oncology (45) 45
male (39) 39
middle aged (39) 39
female (38) 38
aged (34) 34
adult (32) 32
neoplasms - drug therapy (26) 26
index medicus (19) 19
pharmacology & pharmacy (19) 19
antineoplastic agents - adverse effects (14) 14
aged, 80 and over (13) 13
cancer (13) 13
antineoplastic agents - pharmacokinetics (11) 11
article (10) 10
pharmacokinetics (10) 10
antineoplastic agents - administration & dosage (9) 9
dose-response relationship, drug (9) 9
tumors (9) 9
antineoplastic agents - therapeutic use (8) 8
chemotherapy (8) 8
drug administration schedule (8) 8
phase-i (8) 8
toxicity (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
infusions, intravenous (7) 7
maximum tolerated dose (7) 7
phase i (7) 7
suramin - adverse effects (7) 7
drug therapy (6) 6
medicine & public health (6) 6
neoplasms - pathology (6) 6
neutropenia - chemically induced (6) 6
research (6) 6
carcinoma (5) 5
cells (5) 5
clinical trials (5) 5
dosage and administration (5) 5
drug interactions (5) 5
expression (5) 5
health aspects (5) 5
inhibition (5) 5
neoplasms - blood (5) 5
neoplasms - metabolism (5) 5
pharmacology/toxicology (5) 5
prospective studies (5) 5
solid tumors (5) 5
thrombocytopenia - chemically induced (5) 5
treatment outcome (5) 5
area under curve (4) 4
camptothecin - analogs & derivatives (4) 4
care and treatment (4) 4
doxorubicin (4) 4
invitro (4) 4
leukopenia - chemically induced (4) 4
models, biological (4) 4
mtor (4) 4
pharmacology (4) 4
prostate-cancer (4) 4
risk factors (4) 4
suramin (4) 4
suramin - administration & dosage (4) 4
acetylation (3) 3
analysis (3) 3
antineoplastic agents (3) 3
antineoplastic agents - toxicity (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
breast cancer (3) 3
camptothecin - pharmacokinetics (3) 3
cancer research (3) 3
cell lung-cancer (3) 3
clinical trials, phase i as topic (3) 3
continuous infusion (3) 3
diarrhea - chemically induced (3) 3
exocytosis (3) 3
exposure (3) 3
fatigue (3) 3
isoquinolines - adverse effects (3) 3
isoquinolines - pharmacokinetics (3) 3
medicine (3) 3
metastatic colorectal-cancer (3) 3
naphthalimides (3) 3
neoplasms - genetics (3) 3
nsc-308847 (3) 3
original reports (3) 3
paclitaxel (3) 3
paramecium (3) 3
pharmacodynamics (3) 3
pharmacogenetics (3) 3
phase-ii (3) 3
phenotype (3) 3
phosphorylation (3) 3
prostatic neoplasms - drug therapy (3) 3
receptor (3) 3
renal-cell carcinoma (3) 3
retrospective studies (3) 3
risk (3) 3
trichocyst (3) 3
uracil - analogs & derivatives (3) 3
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Law (Bora Laskin) - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Stacks (1) 1
Law (Bora Laskin) - Law Faculty Library (1) 1
Massey College (Robertson Davies) - Rare Book (1) 1
Robarts - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 7, pp. 1119 - 1127
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2018, Volume 36, Issue 16, pp. 1611 - 1618
Purpose Stereotactic body radiotherapy (SBRT) may stimulate innate and adaptive immunity to augment immunotherapy response. Multisite SBRT is an emerging... 
RESPONSES | CELLS | ONCOLOGY | IMMUNOTHERAPY | ANTITUMOR IMMUNITY | CANCER | RADIATION-THERAPY | ORIGINAL REPORTS
Journal Article
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2018, Volume 118, Issue 8, pp. 1042 - 1050
Journal Article
Investigational New Drugs, ISSN 0167-6997, 06/2017, Volume 35, Issue 3, pp. 298 - 306
Journal Article
American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 10/2018, Volume 41, Issue 10, pp. 963 - 966
Objectives: For patients with unresectable or metastatic thymic epithelial neoplasms, few therapy options are available and outcomes are poor. This case series... 
capecitabine | thymic carcinoma | thymoma | celecoxib | ONCOLOGY | EPITHELIAL TUMORS | EXPRESSION | CARCINOMA | Dosage and administration | Celecoxib | Thymoma | Drug therapy | Capecitabine
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 8/2018, Volume 82, Issue 2, pp. 309 - 317
Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor. Metformin may potentiate mTOR inhibition by sirolimus while mitigating its adverse effects. We... 
Pharmacodynamics | Medicine & Public Health | Sirolimus | Oncology | Cancer Research | Metformin | Solid tumors | Pharmacology/Toxicology | P70S6K and mTOR | TARGET | RISK | MTOR | ONCOLOGY | PATHWAY | PHARMACOLOGY & PHARMACY | GENERATION | COHORT | CANCER PREVENTION | PHASE-I | Leukocytes, Mononuclear - metabolism | Phosphorylation | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Neoplasms - blood | Aged, 80 and over | Adult | Female | Metformin - administration & dosage | Ribosomal Protein S6 Kinases, 70-kDa - blood | Leukocytes, Mononuclear - drug effects | TOR Serine-Threonine Kinases - blood | Metformin - pharmacology | Sirolimus - pharmacology | Neoplasms - drug therapy | Biomarkers, Tumor - blood | Drug Synergism | Sirolimus - administration & dosage | Pilot Projects | Adolescent | Aged | Medicine, Experimental | Medical research | Care and treatment | Hypoglycemic agents | Leptin | Tumors | TOR protein | Toxicity | Insulin-like growth factor I | Test procedures | Leukocytes (mononuclear) | Triglycerides | Pharmacology | Rapamycin | Insulin-like growth factors | Insulin | Patients | Peripheral blood mononuclear cells | Biomarkers | Inhibition | mTOR | p70S6K | pharmacodynamics | solid tumors | sirolimus
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 12/2019, Volume 59, Issue 12, pp. 1632 - 1640
This study investigated the time course and magnitude of the pharmacokinetic interaction between capecitabine and the cytochrome P450 (CYP) 2C9 substrate... 
pharmacokinetics | capecitabine | CYP2C9 | celecoxib | drug‐drug interaction | Cytochrome | Plasma | Warfarin | Cytochrome P450 | Drug interactions | Pharmacology | Exposure | Celecoxib | Substrates | Confidence intervals | Equivalence | Drug interaction | Cytochromes P450 | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. TPS3122 - TPS3122
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e14066 - e14066
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2015, Volume 21, Issue 22, pp. 5092 - 5099
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2019, Volume 37, Issue 8_suppl, pp. 34 - 34
Journal Article
19.